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ABSTRACT
Aims and background. The microenvironment has a well recognized role in breast
cancer progression. Despite different theories, the mechanism of early pregnancy
protection in mammary carcinogenesis is unknown. Since pregnancy is responsible
for mammary gland differentiation, we tested the hypothesis that differentiated
mammary epithelial cells may inhibit breast cancer progression. In other words, the
protective role of early pregnancy could be due to the inhibitory influences of the
more differentiated mammary tissue.
Methods. In order to test our hypothesis, we used 30 female Balb/c nude mice and
MCF-7 cells of breast adenocarcinoma. The female mice were divided into two test
groups, group I (GI) and group II (GII), and a control group. In GII, the animals were
submitted to epithelial removal in the left fourth inguinal mammary gland at 3 weeks
of age. Both groups were given continuous hormonal treatment to simulate the preg-
nancy development of the mammary gland. Two million MCF-7 cells were then in-
jected into the fourth inguinalmammary gland (GI) or in the respective clearedmam-
mary fat pad (GII). Five weeks later the mice were sacrificed and their tumors re-
moved. Tumor development rates and tumor volumes were determined and prolifer-
ation and apoptosis were evaluated by immunohistochemistry.
Results. Tumors of GII mice had a larger mean volume than those of GI mice (P =
0.001, Mann-Whitney U-test) and an apparent increase in proliferation, demonstrat-
ed by a higher staining intensity for proliferating cell nuclear antigen (PCNA). As tu-
mors presented caspase 8 staining, there may be apoptotic activation involved in cell
death, mainly through an extrinsic pathway.
Conclusions. These results suggest that a differentiated intact mammary gland may
have an inhibitory influence on mammary tumor growth in mice. Free full text avail-
able at www.tumorionline.it
Introduction
Tumor formation can be prevented by suppressing carcinogenesis or blocking tu-
mor promotion. In experimental models, administration of a combination of antiox-
idant micronutrients has been correlated with a protective effect in breast cancer, es-
pecially due to a decreased incidence of tumors with a better prognosis1-3. Prevention
of mammary carcinogenesis can also be achieved by pregnancy or by administration
of hormones such as progesterone, estrogen and human chorionic gonadotropin in
animal models4,5.
Although there are several epidemiological parameters which may influence breast
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cancer incidence, early full-term pregnancy is consid-
ered by many authors as one of the most important fac-
tors in the decrease of the lifetime breast cancer risk4,6.
Women bearing a child before the age of 20 have an ap-
prox. 50% lower risk of developing breast cancer than
other women. However, a recent meta-analysis demon-
strated that only hormone-responsive breast tumors are
susceptible to the beneficial effects of parity7. It has also
been shown that pregnancy induces a unique genomic
signature in the epithelial compartment of the human
breast8. In this study, stroma was removed by microdis-
section, although different cellular populations were
not considered in the epithelial compartment. These
permanent changes in gene expression were also
demonstrated in hormonally treated rats9.
Four main theories have been put forward to explain
the protective role of pregnancy. According to the first
theory, hormonal changes, namely in estradiol, pro-
lactin and growth hormone levels, are responsible for
the parity protection10. In animal models, both pro-
lactin and growth hormone are reduced in parous com-
pared to nulliparous animals after adjustment for age.
These hormonal changes might result in a lower expres-
sion of estrogen receptors (ER) and epidermal growth
factor receptors in epithelial cells, decreasing their car-
cinogenic susceptibility. The second theory focuses on
the role of cell differentiation, which is maintained after
involution, and hypothesizes that luminal cells may
have a decreased ability to proliferate, hence becoming
less susceptible to carcinogenic stimuli11. The third hy-
pothesis is based on cancer stem cell theory12,13. It states
that pregnancy decreases the number of mammary
stem cells, which in turn are potentially susceptible to
malignant transformation14, although recent studies by
the same group have shown the opposite in mature
adult mice15. Finally, since the protection due to preg-
nancy is specific for ER-positive tumors, the last theory
considers that it may be mediated by changes in estro-
gen responsiveness, in a direct or paracrine way,
through ER-dependent or ER-independent mecha-
nisms7. All 4 theories focus on the decreased suscepti-
bility of mammary epithelial cells to carcinogenic trans-
formation after pregnancy, but none of them considers
the differentiated epithelium itself as being able to in-
hibit tumor progression, even if the cells maintain their
ability to initiate the carcinogenic process.
Some authors have stressed the importance of mi-
croenvironment and extracellular matrix remodeling
during pregnancy and involution in the breast cancer
risk16. A key question that is still unanswered is whether
the refractoriness is intrinsic to the mammary epithelial
cells and/or mediated by persistent alterations in the
host environment5.
A previous study revealed that, when epithelial cells of
mammary glands from virgin female rats were exposed
to a potent carcinogen like MNU (methylnitrosourea)
and then transplanted into pregnant female rats, the tu-
mor incidence in the pregnant rats was lower than in
the host virgin female rats17. This study demonstrated
the relevance of the surrounding environment in car-
cinogenesis, although it failed to establish if it only in-
hibits cell initiation or is able to inhibit tumor growth.
Authors from the same group recently published anoth-
er study using a similar animal model approach to
demonstrate that mammary cancer development can
be blocked by inhibiting or blocking promotion and
progression of carcinogen-initiated cells (not directly
affecting initiation) and that this may be related to the
protection conferred by an early pregnancy18. In our
study we therefore tested the hypothesis that differenti-
ated mammary epithelium by an early pregnancy may
inhibit breast cancer growth and progression.
To approach our hypothesis, we used previously de-
veloped models of pregnancy in mice and determined
the influence of the differentiated intact mammary
gland (compared to the cleared mammary fat pad) in
tumor growth after the injection of tumor cells.
Material and methods
Thirty female Balb-c nude mice were used in this re-
search, 20 in 2 test groups and 10 in a control group. All
experimental procedures performed in the mice were
approved by the National Animal Care Institute and
were according to institution guidelines. Animals were
maintained in laminar flow rooms under constant tem-
perature and humidity on a 12-hour light, 12-hour dark
cycle. Sterile laboratory chow and water were available
ad lib. Surgical procedures were performed under ster-
ile conditions.
At 3 weeks of age, 20 mice were randomly allocated to
2 groups: group I (GI; n = 10) and group II (GII; n = 10).
GII mice were submitted to surgical removal of the ep-
ithelium of the fourth inguinal mammary gland by a
previously described procedure with slight modifica-
tions19.
When themice were 8 weeks old, estrogen (400 µg/kg)
and progesterone (40 mg/kg) lipid solutions were ad-
ministered daily for 21 days by dorsal subcutaneous in-
jections in both groups to simulate the pregnancy de-
velopment of the mammary gland20. Two million MCF-
7 cells (purchased from ATCC) were injected into the
fourth inguinal mammary gland (GI) or the respective
cleared mammary fat pad (GII) when the mice were 11
weeks old. Mice received estradiol benzoate supple-
mentation (1 mg/kg s.c.) every week after cell injection.
These experiments were controlled for hormonal ad-
ministration by the use of a control group of 10 mice
with non-hormone-stimulated intact mammary glands.
Mouse weight and tumor development were meas-
ured weekly. Five weeks after cell injection, the mice
were sacrificed by cervical dislocation. Macroscopic tu-
mors were excised and tumor volumes calculated using
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the following equation:V = (a2 * b)/2, whereV represents
the tumor volume, a the larger axis and b the shorter ax-
is of the tumor.
Tissue fragments were fixed in 10% phosphate-
buffered formalin and embedded in paraffin. Five-µm
sections were obtained from the paraffin blocks and
stained with hematoxylin and eosin for histological ex-
amination. Immunohistochemistry was performed for
PCNA (Lab Vision), caspase 3 (Lab Vision – proenzyme
not cleaved) and caspase 8 (Affinity BioReagents) ac-
cording to a simple 2-step visualization system of very
high sensitivity (Dako Envision Systems – kits K4010
and K4012, for rabbit and mouse primary antibodies,
respectively). We used heat-induced antigen retrieval
with pH 6 citrate buffer. Tumors with strong staining of
PCNA and caspase 8 and tonsillar tissues, which stain
strongly for caspase 3, were used as controls for the im-
munochemical analyses. A blind study was performed
by 2 pathologists to obtain the immunohistochemistry
results. Immunostaining areas were calculated using in-
formatics tools and PCNA immunostaining intensities
were evaluated by comparison with a control tumor us-
ing a 0-3 scale (0 – no staining; 1 – lower than control; 2
– equal to control; 3 – higher than control)21.
Tumor volumes and areas of immunostaining were
statistically evaluated with the Mann-Whitney U-test.
The number of developed tumors was analyzed using
Fisher’s exact test. P values <0.05 were considered sig-
nificant.
Results
Nine mice, 3 in each group, were excluded from the
study because of early death caused by technical errors.
The remaining mice had no significant weight differ-
ences. In each tumor-bearing mouse, only 1 tumor ap-
peared at the graft site. In GI, 4mice (57%) developed tu-
mors, while all GII mice (P = 0.096, Fisher’s test) and 3
control groupmice (43%; P = 0.5, Fisher’s test) developed
tumors. The mean tumor volume (MTV, calculated tak-
ing into account mice with no tumors) was 5.4 mm3 and
56.9 mm3 in GI and GII, respectively (P = 0.001, Mann-
Whitney U-test). Similar differences were found when
the mean tumor volume was calculated in tumor-bear-
ing mice only. Control group tumor volumes were not
statistically different from GI tumor volumes (Table 1).
All tumors in both test groups had a high proliferation
index (more than 50% of tumor cells stained with PCNA)
as evaluated by immunohistochemistry. The staining per-
centageswerenot significantly different between the 2 test
groups (P = 0.382, Mann-Whitney U-test). However, the
immunostaining intensitywashigher inGII thanGI (Table
2). There were no significant differences in immunostain-
ing intensity between GI and the control group.
Caspase 8 and caspase 3 immunostaining was identi-
cal between groups. About half of the cells in each tu-
mor stained for caspase 8 and only a few tumors pre-
sented vestigial staining for caspase 3, despite its posi-
tivity in the control group (data not shown).
Discussion
Tumor heterogeneity arises from different mutations
and tumors are unique and complex entities not sus-
ceptible to inhibitory or antigrowth stimuli. Neverthe-
less, based on previous studies17,18, we hypothesized
that a differentiated normal mammary epithelium may
itself inhibit breast cancer progression. Some recent in
vitro studies also state that normal mammary epithelial
cells exert an inhibitory effect via paracrine pathways22.
We have improved on a previously used experimental
model by surgically removing the mammary epithelium
and leaving the remaining clearedmammary fat pad in-
tact for receiving cells or tissue transplants. The estradi-
ol and progesterone administered in this experiment
are able to simulate the development of a pregnant
gland. There was a lag time between the surgical proce-
dure, hormone administration, and cell injection, to
make sure that surgery did not interfere in tumor
growth.
All mice of GII but only some of GI developed tumors.
The tumors of GII mice were also larger than those of
GI mice. Within a single tumor cell line, there is a cer-
tain phenotypic variability due to epigenetic influ-
ences. Some of these variants may be more resistant to
the proposed inhibitory effect and this may explain the
appearance of a few small tumors in GI. By injecting the
same number of tumor cells from the same cell line in
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Table 1 - Evaluation of final weight, number of tumor-pre-
senting mice and mean tumor volumes
Group I Group II Control group
Weight of mice (g) 22.7 21.5 21.7
Tumor-presenting mice (%) 4/7 (57%) 7/7 (100%) 3/7 (43%)
(P = 0.096)* (P = 0.5)*
MTV (mm3) in all mice 5.4 56.9 2.7 (P = 0.155)°
(P = 0.001)°
MTV (mm3) 9.5 56.9 7 (P = 0.086)°
in tumor-bearing mice (P = 0.003)°
*Fisher test. °Mann-Whitney U-test. MTV, mean tumor volume.
Table 2 - PCNA immunostaining intensities
0 1 2 3
Group I - 1 2 1
Group II - - 2 5
Control group - 1 1 1
PCNA, proliferating cell nuclear antigen. 0, no staining; 1, lower
than control; 2, equal to control; 3, higher than control.
an intact mammary gland and a cleared mammary fat
pad and obtaining different tumor outcomes, we
demonstrated that the differentiated mammary gland
may inhibit tumor growth. Tumors of control group
mice with non-hormone-stimulated intact mammary
glands presented no statistical difference when they
were compared with tumors of GI mice. This suggests
that epithelial cells in general (or at least a subpopula-
tion of them) may have these inhibitory effects, and
that their number and position within the mammary
gland after pregnancy may be an important factor in its
protection.
There are some limitations to this study which should
be mentioned and discussed. Despite the lag time be-
tween surgery and other procedures, a sham operation
should have been performed in GII mice to avoid bias
related to wound healing, which is known to promote
tumor growth. Moreover, we used a single ER-present-
ing cell line in this study, because pregnancy protection
seems to be specific for ER-positive tumors. However,
other breast cancer cell lines expressing different recep-
tors should be tried in the future. Finally, we sought to
address the question of whether the normal mammary
epithelium itself may inhibit tumor promotion. Howev-
er, by removing the epithelium in very young mice, the
stroma and extracellular matrix may have developed
differently. Thus, we did not discard the role of the mi-
croenvironment in tumor growth.
A hypothetic explanation for the inhibitionmay be re-
lated to the normal differentiation process of the mam-
mary gland. Progenitor cells proliferate and differenti-
ate in a limited way and, when there is a functionally
sufficient contingent of terminally differentiated cells,
progenitor cells should be susceptible to inhibitory
paracrine signals (cytokines) derived from the same dif-
ferentiated cells. Taking into account well-known genet-
ic and phenotypic similarities between tumor and pro-
genitor cells13, we may consider that inhibitory path-
ways derived from normal differentiated cells may be
preserved and still have an effect on tumor progression.
Further experiments in normal mammary gland differ-
entiation will contribute towards a better understand-
ing of tumor-epithelium interactions.
In this study we do not refute previous theories con-
cerning the role of pregnancy in protecting against
breast cancer, although we have demonstrated that the
influence of normal mammary epithelium in breast
cancer progression should also be taken into considera-
tion for a complete approach to the study of this role. By
administering the same amount of hormones in both
groups, we showed that hormonal changes on their own
cannot account for the parity protection10. By injecting
tumor cells, we demonstrated that although there are
changes in mammary gland properties during pregnan-
cy, its protective role also cannot be explained solely by
lower susceptibility to carcinogenic stimuli of parous
mammary cells11,14.
The previously referred concepts may be integrated in
the initiation/promotion/progression model of cancer,
considering either cancer stem cells or clonal evolution
models23,24. A mutation in a stem cell or progenitor cell
would initiate the process. However, this mutated cell
would be controlled by the equilibrium between stimu-
latory and inhibitory factors. If this equilibrium were
lost (for example, in chronic inflammation or other
pathological conditions that destroy the normal differ-
entiated environment, thus removing tumor inhibi-
tion), the promotion phase would begin. Later, the ac-
cumulation of further mutations and phenotypic
changes in tumor cells would permit tissue invasion
and systemic dissemination characteristic of the pro-
gression phase.
Breast cancer promotion and progression are blocked
by previous pregnancies. According to our results, this
blocking may be also due to the inhibitory influence of
the differentiated mammary epithelium. Further in-
sight into this influence may elucidate the protective
role of pregnancy in breast cancer, and this will aid in
the development of new prevention and treatment
strategies.
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